Fagron to pay $22.5 million to settle U.S. allegations over inflated prices

Pharmaceutical supplier Fagron Holding USA LLC will pay $22.5 million to resolve allegations that its subsidiaries inflated average wholesale prices for compound drug ingredients and submitted fraudulent claims to federal healthcare programs, the U.S. Department of Justice said on Thursday.